



Arrowhead Pharmaceuticals, Inc.  
Investor Relations Department  
225 South Lake Avenue  
Suite 1050  
Pasadena, CA 91101  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: ARWR**

Last Trade:	5.72
Trade Time:	4:15 PM ET Jan 12, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.42 - 6.25
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Dec 27, 2017*  
[Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors](#)
- Dec 22, 2017*  
[Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV](#)
- Dec 20, 2017*  
[Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT](#)
- Dec 18, 2017*  
[Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635\(C\)\(4\)](#)
- Dec 12, 2017*  
[Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results](#)

### Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- Dec 12, 2017*  
[Annual Report \(10-K\)](#)
- Feb 1, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Feb 6, 2017*  
[Quarterly Report \(10-Q\)](#)